

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

SEMAGLUTIDE LONG-ACTING INJECTION (SYH9017) OBTAINS CLINICAL TRIAL APPROVAL

The board of directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the Semaglutide Long-acting Injection (SYH9017) (the “**Product**”), a GLP-1 receptor agonist developed by the Group, has obtained approval granted by the National Medical Products Administration of the People’s Republic of China to conduct clinical trials in China.

The Product is the first once-monthly semaglutide preparation obtaining clinical trial approval in China. Utilising the Group’s long-acting delivery technology platform and excipients with good biocompatibility, the Product is injected subcutaneously to form a gel depot that enables long-acting drug delivery. Compared with the once-weekly semaglutide injection on the market, the Product is expected to extend dosing to once per month, significantly improving patient medication adherence and possessing distinct clinical advantages. Preclinical studies demonstrated that compared with the semaglutide injection on the market, the Product had comparable weight loss efficacy, favorable safety profile and significantly prolonged half-life, supporting clinical development of the once-monthly preparation.

The indication for this clinical trial approval is weight management in adults who are overweight or obese, along with a reduced-calorie diet and increased physical activity. In addition, the Product has the potential for the treatment of type 2 diabetes and reduction of cardiovascular disease risk, providing a promising clinical development value. The Product represents the Group’s first long-acting once-monthly preparation of GLP-1. The clinical trial approval lays a solid foundation for the development of other long-acting multi-target GLP-1 products.

By order of the Board
CSPC Pharmaceutical Group Limited
CAI Dongchen
Chairman

Hong Kong, 20 December 2024

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin and Mr. CHEN Weiping as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as independent non-executive directors.